SGLT2 inhibitors

154 Unmasking patients’ insight into SGLT2 inhibitors: a collaborative quality improvement project to enhance patient education and safety
Patrick Tran, Lior Saad, Pratyusha Saha, Mohamed Mohamed, Michael Kuehl, Prithwish Banerjee

Heart Jun 2024, 110 (Suppl 3) 163-165; DOI: 10.1136/heartjnl-2024-BCS.151
154 Unmasking patients’ insight into SGLT2 inhibitors: a collaborative quality improvement project to enhance patient education and safety
Patrick Tran, Lior Saad, Pratyusha Saha, Mohamed Mohamed, Michael Kuehl, Prithwish Banerjee

Heart Jun 2024, 110 (Suppl 3) A163-A165; DOI: 10.1136/heartjnl-2024-BCS.151
155 Impact of SGLT2 inhibition on reverse cardiac remodeling in patients with heart failure: a systematic review and meta-analysis
Patrick John Savage, Lana Dixon, Jamie Coburn, Brian Cox, Michael Shahmohammadi, David J Grieve, Chris Watson

Heart Jun 2024, 110 (Suppl 3) A165-A167; DOI: 10.1136/heartjnl-2024-BCS.152
150 Do sglt2 inhibitors improve survival in heart failure with any ejection fraction?
Ko Yi, Suzanne Wong, Kenneth Wong, Mohammad Al-riyahi

Heart Jun 2023, 109 (Suppl 3) A175-A177; DOI: 10.1136/heartjnl-2023-BCS.150
134 Utilisation of sodium glucose transport protein 2 (sglt2) inhibitor in patients with cardiac resynchronisation therapy (crt) device: a uk district general hospital perspective
Ronald Manorekang, Nathan Price, Iyad Ahmed, Chris Hayes

Heart Jun 2022, 108 (Suppl 1) A100-A101; DOI: 10.1136/heartjnl-2022-BCS.134
138 Applicability of use of sodium- glucose co-transporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF) at London northwest university heathcare NHS trust
Oltiana Lakra, Angelica Sharma, Zahraa Al-Dulaimi, Jaskaran Sethi, Elaine Hui, Jaymin S Shah

Heart Jun 2021, 107 (Suppl 1) A105; DOI: 10.1136/heartjnl-2021-BCS.135
150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?
Jacquelyn Hooper, Steven Shaw, Paul Callan, Simon Williams

Heart Jun 2021, 107 (Suppl 1) A115; DOI: 10.1136/heartjnl-2021-BCS.147
198 Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease – are we missing a trick?
David Higson, Andrew Turley

Heart Jun 2021, 107 (Suppl 1) A153-A154; DOI: 10.1136/heartjnl-2021-BCS.194
BS16 The role of parasympathetic nervous system in the infarct-limiting effect of SGLT2 inhibitors
Maryna Basalay, Sean Davidson, Derek Yellon

Heart Jun 2021, 107 (Suppl 1) A164; DOI: 10.1136/heartjnl-2021-BCS.214
101 Heart failure, diabetes and use of SGLT2 inhibitors – a missed opportunity
Soham Coomer, Shruti Jain, Thet Tun, Somnath Kumar

Heart Jul 2020, 106 (Suppl 2) A79-A80; DOI: 10.1136/heartjnl-2020-BCS.101

Log in using your username and password

Main menu

Log in using your username and password

You are here

SGLT2 inhibitors